

## PUBLIKATIONEN

### Praktischer Arzt Ali Sigaroudi

#### Publikationen

**2019 Sigaroudi A**, Jetter A, Mueller TF, Kullak-Ublick G, Weiler S. Severe reduction in tacrolimus concentrations with concomitant metamizole (dipyrone) therapy in transplant patients. Eur J Clin Pharmacol.

**2018** Willkommen D, Lucio M, Moritz F, Forcisi S, Kanawati B, Smirnov KS, Schroeter M, **Sigaroudi A**, Schmitt-Kopplin P, Michalke B. Metabolomic investigations in cerebrospinal fluid of Parkinson's disease. PLoS One.

**2018** Willkommen D, Lucio M, Schmitt-Kopplin P, Gazzaz M, Schroeter M, **Sigaroudi A**, Michalke B. Species fractionation in a case-control study concerning Parkinson's disease: Cu-amino acids discriminate CSF of PD from controls. J Trace Elem Med Biol.;49:164-170

**2018 Sigaroudi A**, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F. Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects. Pharmacology. 2018;102(3-4):133-137. Epub 2018 Jul 6

**2017** Weber NT, **Sigaroudi A**, Ritter A, Boss A, Lehmann K, Goodman D, Farese S, Weiler S, Mueller TF. Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report. BMC Nephrol. 2017 Dec 12;18(1):360

**2017 Sigaroudi A**, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F. Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples. Pharmacology. 2017 Sep 21;101(1-2)

**2017 Ali Sigaroudi**, PD Dr. med. Stefan Weiler. Heparininduzierte Thrombozytopenie Typ II. Swiss Medical Forum. 2017; 17 Aug

**2016 Sigaroudi A**, Stelzer C, Braun T, Frechen S, Hüttner S, Schröter M, Kinzig M, Fuhr U, Holzgrabe U, Sörgel F. Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples. Pharmacology. 2016 Apr 23;98(1-2):70-72

**2016 Sigaroudi A**, Kullak-Ublick GA, Weiler S. Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine. Eur J Clin Pharmacol. 2016 Mar;72(3):377-8

**2015** Frechen S, Suleiman AA, Mohammad Nejad **Sigaroudi A**, Wachall B, Fuhr U. Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhaler. Drug Metab Pharmacokinet. 2015 Dec;30(6):391-9